Yan Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yan Wang has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
Jiayi Ma
Department of Breast Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China
1 shared publication- Jinsong Lu
Department of Breast Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China
1 shared publication - Liang Zhu
Department of Breast Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200000, China
1 shared publication Liheng Zhou
Department of Breast Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China
1 shared publication- Wenjin Yin
Department of Breast Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China
1 shared publication Yanping Lin
Department of Breast Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China
1 shared publication
Latest Publications
- Open Access
- 1 September 2025
- Published by SAGE Publications in Therapeutic Advances in Medical Oncology
- Vol. 17
Metronomic chemotherapy of paclitaxel plus cisplatin in patients with metastatic breast cancer: a target trial emulation study
Background: As metastasis drives the majority of breast cancer-related deaths, improving outcomes for metastatic breast cancer (MBC) remains a crucial challenge. Observational studies using target trial emulation are increasingly applied to estimate treatment effects, providing insights when randomized trials are not viable. Objectives: To estimate the effect of progression-free survival (PFS) of metronomic chemotherapy of weekly paclitaxel plus cisplatin (DP) compared with treatment of the physician’s choice (TPC) for MBC. Design: This analysis was designed as a retrospective cohort study according to STROBE criteria. Methods: This retrospective cohort study compared metronomic chemotherapy of weekly DP versus TPC in MBC. The DP regimen included paclitaxel (80 mg/m 2 ) on days 1, 8, 15, 22 and cisplatin (25 mg/m 2 ) on days 1, 8, 15 in a 28-day cycle. Women aged ⩾18 years with MBC treated with at least one prior therapy between April 2014 and January 2023 at Renji Hospital were included. Propensity score matching (1:3) adjusted for confounding. The matched cohort subsequently underwent emulation of a randomized target trial, including cloning, censoring and weighting. The primary endpoint was PFS. Results: Among 313 matched patients (83 on DP, 230 on TPC), DP showed a median PFS of 13.5 months (95% CI 10.3–16.6) versus 7.9 months (95% CI: 6.7–9.1) for TPC (hazard ratio (HR) 0.77, 95% CI 0.60–0.99). Target trial emulation further improved PFS in the DP arm to 14.1 months (95% CI: 13.3–16.6) versus 8.3 months (95% CI: 8.0–8.6) for TPC (HR 0.59, 95% CI: 0.54–0.64). Subgroup analysis and sensitivity analyses confirmed result robustness. Conclusion: This study demonstrates that weekly metronomic DP chemotherapy reduces disease progression in MBC patients, particularly in first-line settings. These findings support its potential as a treatment option and warrant further study for broader application.
- 1 September 2025
- Published by SAGE Publications in Therapeutic Advances in Medical Oncology
- Vol. 17
Open AccessMetronomic chemotherapy of paclitaxel plus cisplatin in patients with metastatic breast cancer: a target trial emulation study
Background: As metastasis drives the majority of breast cancer-related deaths, improving outcomes for metastatic breast cancer (MBC) remains a crucial challenge. Observational studies using target trial emulation are increasingly applied to estimate treatment effects, providing insights when randomized trials are not viable. Objectives: To estimate the effect of progression-free survival (PFS) of metronomic chemotherapy of weekly paclitaxel plus cisplatin (DP) compared with treatment of the physician’s choice (TPC) for MBC. Design: This analysis was designed as a retrospective cohort study according to STROBE criteria. Methods: This retrospective cohort study compared metronomic chemotherapy of weekly DP versus TPC in MBC. The DP regimen included paclitaxel (80 mg/m 2 ) on days 1, 8, 15, 22 and cisplatin (25 mg/m 2 ) on days 1, 8, 15 in a 28-day cycle. Women aged ⩾18 years with MBC treated with at least one prior therapy between April 2014 and January 2023 at Renji Hospital were included. Propensity score matching (1:3) adjusted for confounding. The matched cohort subsequently underwent emulation of a randomized target trial, including cloning, censoring and weighting. The primary endpoint was PFS. Results: Among 313 matched patients (83 on DP, 230 on TPC), DP showed a median PFS of 13.5 months (95% CI 10.3–16.6) versus 7.9 months (95% CI: 6.7–9.1) for TPC (hazard ratio (HR) 0.77, 95% CI 0.60–0.99). Target trial emulation further improved PFS in the DP arm to 14.1 months (95% CI: 13.3–16.6) versus 8.3 months (95% CI: 8.0–8.6) for TPC (HR 0.59, 95% CI: 0.54–0.64). Subgroup analysis and sensitivity analyses confirmed result robustness. Conclusion: This study demonstrates that weekly metronomic DP chemotherapy reduces disease progression in MBC patients, particularly in first-line settings. These findings support its potential as a treatment option and warrant further study for broader application.